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Abstract
Background: There are few reports in the literature of invasive infection caused by Brevundimonas
vesicularis in patients without immunosuppression or other predisposing factors. The choice of
antimicrobial therapy for bacteremia caused by the pathogen requires more case experience to be
determined.
Case presentation: The case of a 40-year-old previously healthy man with subacute endocarditis
proposed to be contributed from an occult dental abscess is described. The infection was found to
be caused by B. vesicularis on blood culture results. The patient recovered without sequelae after
treatment with ceftriaxone followed by subsequent ciprofloxacin therapy owing to an allergic
reaction to ceftriaxone and treatment failure with ampicillin/sulbactam.
Conclusion: To our knowledge, this is the first report of B. vesicularis as a cause of infective
endocarditis. According to an overview of the literature and our experience, we suggest that third-
generation cephalosporins, piperacillin/tazobactam, and ciprofloxacin are effective in treating
invasive B. vesicularis infections, while the efficacy of ampicillin-sulbactam needs further evaluation.
Background
Brevundimonas (formerly Pseudomonas) vesicularis is an aer-
obic nonsporulating and nonfermenting gram-negative
bacillus [1] that has been isolated from the external envi-
ronment [2-5] and human clinical specimens [6-15].
There have been only eight descriptions of infections in
human beings caused by the microorganism, with only
four cases of bacteremia reported in the literature [Table 1,
[8-15]]. Five cases of B. vesicularis infection were attributed
to community sources [10,12-15] and three to nosoco-
mial sources [8,9,11]. Such underlying diseases as autoim-
mune disorders associated with long-term steroid use,
end-stage renal disease treated by hemodialysis, and sickle
cell anemia with functional asplenia contributed to B.
vesicularis infections in 6 of the 8 reported cases due to the
patients' immunocompromised state [Table 1, [8-12,15]].
B. vesicularis infection has therefore been classified as
opportunistic [8-12,15]. We report here a case of infective
endocarditis caused by B. vesicularis in a patient without
comorbid disease. The low number of cases reported of B.
vesicularis infection in humans limits the body of knowl-
edge on the spectrum of disease caused by this pathogen
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as well as optimal treatment regimens. The treatment
course of the current case and previous cases of B. vesicu-
laris infection is further discussed.
Case presentation
The patient was a 40-year-old male admitted for chronic
cough and a 2-month history of intermittent afternoon
fever. He denied both a history of traveling and contact
with animals over the previous 3 months. Associated
symptoms included general malaise, anorexia, and the
loss of 6 kg body weight within the previous 2 months.
On admission, the vital signs were shown as blood pres-
sure: 124/68 mmHg; pulse rate: 80/min; respiratory rate:
22/min; body temperature: 38.5°C. Physical examination
revealed a pansystolic murmur over the apex and left
lower sternal border. An abscess in a molar cavity that
required debridement was found, although the patient
had not complained of dental pain. Laboratory tests
revealed a WBC count of 9250/μL with elevated neu-
trophils (82.7%); normocytic anemia with a hemoglobin
level of 10.4 g/dL; an elevated ESR level (123 mm/1 hr);
and abnormal liver function with AST/ALT of 49/79 IU/L.
A chest x-ray film revealed increased infiltration over the
right upper and lower lobes, and abdominal sonography
showed mild splenomegaly. Diagnosis of pulmonary
tuberculosis was excluded by negative results from serial
acid-fast stain and culture of Mycobacterium tuberculosis.
Transthoracic echocardiography revealed a vegetation
with size of 0.9 cm over the anterior leaflet of mitral valve,
and moderate mitral regurgitation. However, the cardiac
systolic and diastolic functions were normal with the ejec-
tion fraction of 78.9%, fraction shortening of 47.8%. Ulti-
mately, definite subacute endocarditis was diagnosed
according to the Duke criteria, including two blood cul-
ture results of B. vesicularis; the presence of vegetation on
the mitral valve revealed by an echocardiogram (Fig. 1);
and such clinical and laboratory features as fever,
splenomegaly, heart murmur, anemia, Osler's node (Fig.
2),,and Roth's spot (Fig. 3).
The pathogen was identified as B. vesicularis on the basis
of the biochemical characteristics tested by the API ID 32
GN automatic identification system (bioMérieux, Marcy I'
Étoile, France). These included the characteristics of posi-
tive activity of D-maltose/D-glucose oxidation; negative
activity of inositol/D-sorbitol/L-arabinose oxidation; neg-
ative activity of L-alanine/capric acid/potassium 5-
ketogluconate/trisodium citrate decarboxylation; negative
activity of nitrate reduction and indole production. The
organism was susceptible to amikacin, gentamicin, piper-
acillin, aztreonam, cefepime, meropenem, netilmicin,
ampicillin, amoxicillin, ciprofloxacin, cefazolin, cefmeta-
zole, ceftazidime, cefotaxime, ceftriaxone, and ticarcillin,
according to the susceptibility test performed by the disc
diffusion method with interpretation criteria for Pseu-
domonas [16]. The patient was treated with a combina-
tion of cefazolin (2 gm/8 hr) and gentamicin (80 mg/8
hr) as empiric antibiotics during the first 3 days and fever
subsided gradually.
Ampicillin/sulbactam (3 gm/6 hr) was used alternatively
for covering the infection of oral anaerobes while the
Table 1: Summary of reported cases of Brevundimonas vesicularis infection in humans
Reference Age (y)/sex Underlying disease Clinical 
presentation
Treatment/duration Outcome
(8)/NI 54/F SLE, autoimmune 
hepatitis, steroid 
therapy
Necrotizing cellulitis Tobramycin + ceftazidime/30d Survival
(9)/NI 42/F Mitral valve stenosis s/
p mitral valve 
replacement
Septicaemia Piperacillin - tazobactam/14d Survival
(10)/CA 5/M Sickle cell anemia Pneumonia Ceftriaxone + gentamicin/10d Survival
(11)/NI 59–67/both Hemodialysis Septicaemia Cefotaxime + tobramycin/unknown Survival
(12)/CA 60/M Trauma Botryomycosis Cefuroxime- axetil/4 months Survival
(13)/CA 38/M No Acute tonsillitis amoxicillin- clavulanate/3d Survival
(14)/CA 1.25/F No Septic arthritis cefuroxime/12d + oral cephalexin/14d Survival
(15)/CA 55/M Continuous 
ambulatory peritoneal 
dialysis
peritonitis ceftazidime/3d, ceftazidime + vancomycin/4d, 
ciprofloxacin + aztreonam/14d
Survival
current case/CA 40/M No Subacute endocarditis cefazolin + gentamicin/3 d, Ampicillin/sulbactam 
+ gentamicin/5 d, Ceftriaxone + gentamicin/7 d, 
ciprofloxacin/30 d
Survival
Abbreviations:
CA = community-acquired infection;
NI: nosocomial infection. Nosocomial infections are those that originate or occur in a hospital if they first appear 48 hours or more after admission 
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patient underwent removal of the abscessed tooth. Treat-
ment with amipicillin/sulbactam failed, however; the
patient developed a flare-up of fever, the appearance of a
new Osler's node on the fourth digit of the left hand (Fig.
2), and pain in the right femur with right inguinal lym-
phadenopathy. Treatment with a combination of ceftriax-
one (2 gm/12 hr) and gentamicin (80 mg/8 hr) was
administered subsequently. The femoral-inguinal symp-
toms and fever improved gradually with the antimicrobial
therapy and therefore were ascribed to embolism.
Although the clinical symptoms and signs improved after
use of these antibiotics, ciprofloxacin (400 mg/12 hr) was
administered as an alternative due to the eruption of a
skin rash from an allergic reaction after 7 days' treatment
with ceftriaxone. Ultimately, the patient received the treat-
ment regimen for one month and was discharged. There
were no sequelae at 6-month follow-up and the mitral
vegetation disappeared in the follow-up echocardiogram
performed one month after discharge.
Conclusion
Subacute infective endocarditis commonly involves heart
valves already damaged in some way and is most often
caused by one of the Viridans streptococci, such as Strepto-
coccus sanguis, S. mutans, S. mitis, or S. milleri, which nor-
mally live in the mouth and throat. To the best of our
knowledge, this is the first presentation of B. vesicularis
manifesting as subacute endocarditis of the native valve.
The dental cavity, which was the only infective focus
noted, was proposed to be the origin of the infection even
though no direct evidence of Brevundimonas was isolated
from the dental abscess. B. vesicularis has been isolated
from pus culture with tonsil swabs [13], suggesting the
existence of the pathogen in the oral cavity. Furthermore,
in the cases of tonsillitis and septic arthritis, the subjects
had been immunocompetent before the occurrence of
Brevundimonas  infection [13,14]. Therefore, the clinical
significance of the pathogen should not be confined
solely to infections in immunocompromised hosts.
According to researchers at the CDC, B. vesicularis is highly
sensitive to all aminoglycosides (98%), piperacillin
(100%), carbenicillin (94%), and ceftizoxime (94%),
with moderate susceptibility to cefamandole (50%) and
cefoxitin (75%), and lower susceptibility to penicillin
(12%) and ampicillin (22%) [17]. The antibiograms of
isolates from clinical cases were variable, however; most
were determined by the disc diffusion method [[8,9,13],
Table 2]. Our reported case was treated with cefazolin and
Roth's spot on the retina of the left eye Figure 3
Roth's spot on the retina of the left eye.
Transthoracic echocardiogram showing vegetation (0.9 cm)  over the anterior leaflet of mitral valve Figure 1
Transthoracic echocardiogram showing vegetation (0.9 cm) 
over the anterior leaflet of mitral valve.
Osler's node on the fourth digit of the left hand Figure 2
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gentamicin as empiric antibiotics initially, followed by
amipicllin/sulbactam, then ceftriaxone and gentamicin,
followed with ciprofloxacin. The failed clinical response
in our case to ampicillin/sulbactam therapy even though
susceptibility testing has demonstrated that the organism
is susceptible to ampicillin/sulbactam, indicates that
results from the disc diffusion method with reference to
Pseudomonas species are not suitable in guiding antimicro-
bial therapy for B. vesicularis endocarditis. For endocardi-
tis, minimum inhibitory concentration (MIC), minimum
bactericidal concentration and serum bactericidal titer
determination are appropriate to guide antimicrobial
therapy. Our report has the limitation of lacking MIC
determination as the antimicrobial susceptibility testing
method. It is difficult to decide on the best antimicrobial
for invasive infection due to B. vesicularis because of the
low number of reported cases in humans caused by this
pathogen; the fact that isolates come from various coun-
tries or findings from different laboratories; and the lack
of standarized testing. Five of the reported cases [[8,10-
12,14], Table 1] were successfully treated with a second-
or third-generation cephalosporin with or without an
aminoglycoside; two cases were treated with a β-lactam/β-
lactamase inhibitor [[9,13], Table 1]; Two cases were
treated with ciprofloxacin alone or combined with a
monobactam [current case, [15], Table 1]. Our experience
in this case and previous cases of bacteremia suggest that
a third-generation cephalosporin, piperacillin/tazo-
bactam, aztreonam and ciprofloxacin are effective in treat-
ing infection due to B. vesicularis. Though subacute
bacterial endocarditis caused by Pseudomonas spp. should
be appropriately treated for 6 weeks [18], our reported
case was successfully treated with four-week antimicrobial
therapy. To decide the optimal duration of therapy for B.
vesicularis endocarditis, more experience with such case is
required.
In conclusion, since cases of infection due to B. vesicularis
are reported with increasing frequency, our endocarditis
case report reinforces the hypothesis that bacteria can
cause invasive disease in a person without predisposing
disease. More treatment experience and more exact results
from antimicrobial susceptibility testing are required to
improve on present treatment regimens for invasive B.
vesicularis infection.
Table 2: In-vitro antibiotic susceptibility of Brevundimonas vesicularis
Reference Current 
Case*
Choi# (15) Sofer# (14) Chi* (13) Gilad* (9) Oberhelman‡ 
(10)
Planes* (8)
Year 2006 2006 2006 2004 2000 1994 1992
Antibiotics
Ampicillin S N S R R N S
Piperacillin S S S N S S R
Mezlocillin N N N N S S N
Carbenicillin N N N N N S N
Amoxicillin/
clavulanate
SNNNSNN
Piperacillin/
tazobactam
SNNSSNN
Cefazolin S N S R N N S
Cefuroxime N N S S R N N
Cefoxitin N N S N N N S
Cefotaxime S N S S N N S
Ceftriaxone S N S S R S S
Ceftazidime S S S R R S R
Gentamicin S S S R S S S
Tobramycin N N S R S N S
Amikacin S N S S S N S
Doxycycline N N S S N N S
Chloramphenic
ol
NNNSNNS
Cotrimoxazole S N S S S N S
I m i p e n e m NSNSSNN
Aztreonam S S N R R N N
Ciprofloxacin S S S R R S N
Abbreviations: S = susceptible; R = resistant; N = not determined
* Susceptibility was determined by disc diffusion.
‡ Susceptibility was determined by automatic microdiffusion.
# Susceptibility was determined by an unknown method.Publish with BioMed Central    and   every 
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